Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567053 | 0.86 | FFAR1 (0.52) | FFAR1NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL19002576 | 0.85 | HTT (0.53) | FFAR1NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL7720191 | 0.85 | HTT (0.53) | FFAR1NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL7364455 | 0.84 | IDO1 (0.53) | FFAR1NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL4706402 | 0.84 | HTT (0.56) | FFAR1NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL10791043 | 0.82 | FFAR1 (0.54) | FFAR1NPC1RAB9ASMN1; SMN2LDHA | |
| SCHEMBL10072105 | 0.82 | HTT (0.50) | FFAR1NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL4689393 | 0.82 | RAB9A (0.56) | NPC1RAB9APOLBSMN1; SMN2HTT | |
| SCHEMBL13886095 | 0.81 | RAB9A (0.51) | FFAR1NPC1RAB9AAGXTCA1 | |
| SCHEMBL13886143 | 0.81 | ALDH1A1 (0.50) | NPC1RAB9APLA2G4BTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | claimed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | claimed |
| US-6391916-B1 | ANTITUMOR AGENTS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2002-05-21 | — | — | US | claimed |
| CN-122094953-A | 1, 3-Dihydro-2H-pyrrolo [3,4-c ] quinoline derivatives as cGAS inhibitors for the treatment of inflammatory and/or autoimmune diseases | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250122216-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2025-04-17 | — | — | US | disclosed |
| CN-114008065-B | Glycyrrhetinic acid derivatives for the treatment of hyperkalemia | 阿德利克斯股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025040569-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,4-C]QUINOLINE DERIVATIVES AS CGAS INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-02-27 | — | — | WO | disclosed |
| US-12168668-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4331679-A2 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | Shy Therapeutics LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-0786462-B1 | DC107 derivatives | KYOWA HAKKO KOGYO KK (JP) | 2002-09-18 | — | — | EP | disclosed |
| US-6391916-B1 | ANTITUMOR AGENTS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2002-05-21 | — | — | US | disclosed |
| EP-1087973-A1 | IMIDAZOTRIAZOLOPYRIMIDINES USED AS A DRUG HAVING AN ADENOSINE ANTAGONIST ACTIVITY | Boehringer Ingelheim Pharma KG (DE) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000012511-A1 | IMIDAZOTRIAZOLOPYRIMIDINES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999065912-A1 | IMIDAZOTRIAZOLOPYRIMIDINES USED AS A DRUG HAVING AN ADENOSINE ANTAGONIST ACTIVITY | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999033839-A1 | CEPHEM DERIVATIVES AND A METHOD FOR PRODUCING THE COMPOUNDS AND AN ANTIBACTERIAL COMPOSITION CONTAINING THE COMPOUNDS | CHEIL JEDANG CORPORATION (KR) | 1999-07-08 | — | — | WO | disclosed |
| US-5811550-A | Process for the preparation of a 1,3-oxazolidine-5-carboxylic acid | RHONE-POULENC RORER, S.A. (FR) | 1998-09-22 | — | — | US | disclosed |
| US-5733924-A | BACTERICIDES AND ANTITUMOR AGENTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-03-31 | — | — | US | disclosed |
| EP-0786462-A1 | DC107 DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | FFAR1 1078/4885NPC1 962/4885RAB9A 2102/4885 |
| US-20250122216-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | FFAR1 1497/4885NPC1 2024/4885RAB9A 2641/4885 |
| US-12168668-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | FFAR1 1497/4885NPC1 2024/4885RAB9A 2641/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | FFAR1 91/4885NPC1 3730/4885RAB9A 3221/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | FFAR1 658/4885NPC1 2511/4885RAB9A 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.